New synthetic hormone shows promise for rare calcium disorder
NCT ID NCT05239221
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a synthetic parathyroid hormone analog called AZP-3601 in healthy volunteers and patients with chronic hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. The study aimed to check safety and how the drug works in the body. It involved 132 participants across three parts, including single and multiple doses over up to three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZP-3601 (eneboparatide), a synthetic parathyroid hormone analog
- What this could lead to
- If successful, this could lead to a new treatment option for chronic hypoparathyroidism that helps control calcium levels and reduces symptoms.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with small groups and short treatment duration. The drug may not prove effective or safe in larger, longer studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amolyt Pharma Investigational Site Hungary
Budapest, Hungary
-
PRA-EDS
Groningen, 9728, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.